Fresenius in talks to buy Nephromor from Teva, Clalit

Erez Vigodman  picture: Eyal Yitzhar
Erez Vigodman picture: Eyal Yitzhar

Fresenius Medical Care, the world's largest dialysis services company, will pay NIS 350 million for the Israeli dialysis company.

The Nephromor nationwide chain of community dialysis institutes in Israel is slated for sale to dialysis services company Fresenius Medical Care, a subsidiary of German company Fresenius, for NIS 350 million, sources inform "Globes." Nephromor is a private company owned by a number of parties, including Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), owner of about half of the company through its Teva Medical subsidiary, which markets medical equipment in Israel. Another shareholder in Nephromor is Clalit Health Services, which holds it stake through the Mor Institute.

Founded in 1994, Nephromor provides dialysis services - a substitute medical treatment in cases of inadequate kidney functioning. The company also provides related medical services. According to Nephromor's website, the company is the largest dialysis services provider in the Israeli private market.

The private market accounts for 50% of all dialysis services in Israel, and Nephromor performs an estimated 51% of the treatment in the private market. The company currently operates 21 dialysis treatment institutes deployed all over Israel, from Dimona in the south to Karmiel in the north. The trend away from hospital dialysis treatment in favor of community-based treatment has been gathering steam in recent years. In a presentation published by Nephromor three years ago, the company noted that the trend was designed to accommodate patients and improve their quality of life, and that its treatment was less expensive than the corresponding treatment in a hospital. The same presentation asserted that the company was emphasizing the "customer experience" and the friendliness of the procedure for the patient.

Nephromor also offers its services to overseas patients (medical tourism) at $400 per dialysis treatment, not including drugs. The activity of Teva, a shareholder in Nephromor, includes activity it does not have in other countries, among other things the provision of distribution services to third parties, for example. Teva markets and supplies medical equipment and devices through Teva Medical to hospitals, health institutions, and patients in the community. In a corporate responsibility statement published several years ago, it referred to Nephomor's business, saying, "Teva Medical's business in dialysis treatment in hospitals and community centers constitutes a breakthrough in Israel," through which thousands of patients receive complex dialysis treatment in comfort in their homes or nearby. "This solution cuts costs for the medical institutions, thereby freeing up money for many other patients.

"For the purpose of this activity, Teva Medical created a joint company named Nephromor in cooperation with Clalit Health Services," Teva wrote in its report. The sale of Nephromor will be a small exit for Teva, and will probably not have a substantial effect on Teva's financial results. At the same time, the sale fits in with an arrangement in its business being carried out by Teva, managed by Erez Vigodman. For example, in the sphere of special drugs, Teva announced that it was focusing its R&D activity on its core areas: the central nervous system and the respiratory system. Last week, the company sold four oncological R&D assets to a company in the US in a $12 million share swap. The purchaser in this emerging deal is Fresenius Medical Care, the world's largest dialysis company with a market cap of over €30 billion, which is currently conducting due diligence for the acquisition of Nephromor.

Fresenius Medical Care was founded in 1996 as a merger between a company spun off from Fresenius and a US company. The parent company's share is traded at a market cap of over €30 billion. The Fresenius Medical Care share is dual listed on the Frankfurt Stock Exchange and the New York Stock Exchange at a market cap of $25.7 billion. The subsidiary operates in various fields, including the production and distribution of dialysis machines and systems, the production of disposable products used in the dialysis process, and the provision of services to patients. The company operates a chain of over 3,000 dialysis clinics in more than 45 countries.

Most of Fresenius Medical Care's revenue comes from clinics in North America, which generated $10.5 billion out of the company's $15.8 billion in revenue in 2014. The company projects 5-7% growth in revenue in 2015 and a rise of up to 5% in net profit. Net profit in 2015 totaled $1 billion. The company's declared strategy is to expand its business by means of acquisitions, and to enter related fields. In recent years, the company has made several acquisitions that expanded its geographical deployment, for example Liberty Dialysis Holdings in 2012 for $2.2 billion and control of Sound Inpatient Physicians, which provides services to physicians, in July 2014.

As of now, Fresenius Medical Care has no direct services activity in Israel, but markets its products in Israel through Neopharm group subsidiary Eldan.

Published by Globes [online], Israel business news - www.globes-online.com - on March 25, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Erez Vigodman  picture: Eyal Yitzhar
Erez Vigodman picture: Eyal Yitzhar
Bezhalel Machlis  credit: Assaf Shilo/Israel Sun Elbit Systems CEO: Our potential in Europe is huge

Bezhalel Machlis was speaking at an investor conference after the company released 2024 results showing revenue up 14.3%.

Gaza Strip, March 17 2025  credit: Reuters/Anadolu IDF resumes assault on Hamas

Extensive aerial attacks were carried out against targets in the Gaza Strip overnight.

Wiz founders Yinon Costica, Assaf Rappaport, Ami Luttwak, Roy Reznik credit: Avishag Shaar Yishuv Google renews attempt to buy Wiz - report

According to "The Wall Street Journal", Google parent company Alphabet is negotiating to buy the Israeli cloud computing security company for $30 billion.

Orit Strook  credit: Marc Israel Sellem/The Jerusalem Post Finance C'ttee approves NIS 300m coalition funds distribution

The money will mainly go to Religious Zionist party minister Orit Strook's Ministry of Settlements and National Missions.

Dangoor Academy  credit: British Embassy in Tel Aviv British Embassy showcases Israeli healthcare startups

The nine startups participated in the Dangoor HealthTech Academy, a program that connects Israeli startups with the UK healthcare system.

NextVision Stabilized Systems  credit: Shlomi Yosef/Tali Bogdanovsky Next Vision shareholders make NIS 230m exit

A British hedge fund has bought a 2.5% stake in the stabilized cameras company.

Energean CEO Mathios Rigas at the Israel Business Conference   credit: Shlomi Yosef Energean's $1b gas fields sale at risk

The sale of the energy company's asset portfolio in Egypt, Italy and Croatia may fall through because of the buyer's difficulties with the Italian regulator.

Kela Technologies founders Jason Manne, Hamutal Meridor, Alon Dror and Omer Bar Ilan  credit:  Yosef Haim Alterman Defense tech co Kela raises $39m

In response to the events of October 7, Kela has developed a platform for rapid integration of commercial technologies into military systems.

Benjamin Netanyahu  credit: ‎Alex Kolomoisky, Yediot Aharonot Firing the Shin Bet chief: The hurdles

Prime Minister Benjamin Netanyahu says he has "lost trust" in Shin Bet head Ronen Bar. Will this be enough to overcome legal challenges to his dismissal?

Emiliano Calemzuk  credit: PR CEO and "investor group" buying out Reshet 13

CEO Emiliano Calemzuk and the other investors will hold 74% of the television channel, while Len Blavatnik’s Access Industries and WBD will remain with 26%.

Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018